Diagnostic Approach to Clinically Isolated Syndrome with High Probability of Conversion to Multiple Sclerosis

Introduction to Diagnostic Criteria

The presence of a single silent brain lesion in a patient with optic neuritis reduces the probability of monophasic disease, according to the National Institute of Health 1
The American Academy of Neurology recommends that patients with clinically isolated syndrome (CIS) undergo urgent diagnostic evaluation, including MRI of the brain and spinal cord, to confirm dissemination in space and time 1

The National Multiple Sclerosis Society suggests that MRI of the brain and spinal cord with gadolinium should be performed within 24-48 hours to evaluate for lesions in the brain and spinal cord 2, 1, 3
The presence of oligoclonal bands in the cerebrospinal fluid (CSF) is a strong predictor of conversion to multiple sclerosis (MS), with a hazard ratio of 5.1-11.3 1
The European Committee for Treatment and Research in Multiple Sclerosis recommends that patients with CIS undergo lumbar puncture to evaluate for oligoclonal bands and to rule out other conditions, such as infection or inflammation 8, 9

The International Panel on Multiple Sclerosis Diagnosis recommends that patients with CIS be evaluated for neuromyelitis optica spectrum disorder (NMOSD) by testing for anti-AQP4 antibodies, as some treatments for MS can worsen NMOSD 2, 3, 4, 5
The presence of a normal brain MRI and the absence of oligoclonal bands in the CSF make NMOSD less likely, according to the National Institute of Neurological Disorders and Stroke 6, 7

The American Academy of Neurology recommends that patients with CIS be treated with high-dose intravenous methylprednisolone (1000 mg/day for 3-5 days) as soon as possible after diagnosis, without waiting for CSF results 8, 9
The use of plasma exchange should be considered in patients who do not respond to corticosteroids, according to the National Institute of Neurological Disorders and Stroke 8, 9, 5

The National Multiple Sclerosis Society recommends that patients with CIS who have a high risk of conversion to MS (e.g., those with multiple brain lesions or oligoclonal bands) be started on disease-modifying therapy as soon as possible, according to the European Committee for Treatment and Research in Multiple Sclerosis 1
The choice of disease-modifying therapy should be individualized based on the patient's risk factors and preferences, according to the American Academy of Neurology 5

The European Committee for Treatment and Research in Multiple Sclerosis recommends that patients with CIS undergo regular follow-up evaluations, including brain MRI and clinical assessments, to monitor for disease activity and progression 5
The National Institute of Neurological Disorders and Stroke suggests that patients with CIS be monitored for the development of new lesions or worsening of existing lesions on brain MRI, as well as for changes in clinical status 5